NASDAQ:RIGL - Rigel Pharmaceuticals Stock Price, Price Target & More

$3.84 -0.22 (-5.42 %)

(As of 04/22/2018 12:45 PM ET)

Previous Close$3.84

Today's Range$3.73 - $4.19

52-Week Range$2.14 - $4.71

Volume15.40 million shs

Average Volume5.08 million shs

Market Capitalization$565.90 million

P/E Ratio-6.19

Dividend YieldN/A

Beta1.32

About Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and immunoglobulin a nephropathy. Rigel Pharmaceuticals, Inc. has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; BMS for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases. The company was incorporated in 1996 and is based in South San Francisco, California.

Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:RIGL

CUSIP76655960

Webwww.rigel.com

Phone650-624-1100

Debt

Debt-to-Equity RatioN/A

Current Ratio6.41%

Quick Ratio6.41%

Price-To-Earnings

Trailing P/E Ratio-6.19

Forward P/E Ratio-5.41

P/E GrowthN/A

Sales & Book Value

Annual Sales$4.48 million

Price / Sales126.32

Cash FlowN/A

Price / CashN/A

Book Value$0.69 per share

Price / Book5.57

Profitability

EPS (Most Recent Fiscal Year)($0.62)

Net Income$-77,990,000.00

Net MarginsN/A

Return on Equity-100.48%

Return on Assets-82.72%

Miscellaneous

Employees103

Outstanding Shares147,370,000

How to Become a New Pot Stock Millionaire

Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its earnings results on Tuesday, March, 6th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.05. During the same period last year, the firm earned ($0.16) earnings per share. View Rigel Pharmaceuticals' Earnings History.

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Rigel Pharmaceuticals.

What price target have analysts set for RIGL?

5 analysts have issued twelve-month price targets for Rigel Pharmaceuticals' shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate Rigel Pharmaceuticals' share price to reach $7.20 in the next year. View Analyst Ratings for Rigel Pharmaceuticals.

What are Wall Street analysts saying about Rigel Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:

1. Cantor Fitzgerald analysts commented, "Premature to Write-off IgAN for Now. Given the totality of the data and unmet need in IgAN, we have slightly lowered our probability of success for the program. While the data did not meet the primary endpoint of a statistically significant mean change in proteinuria from baseline, several positive trends were found among a pre-specified population of patients with greater than 1,000mg/g of proteinuria. Treatment with 150mg fostamatinib twice daily at 24-weeks led to a median reduction in proteinuria from baseline of 803mg/ g (n=15), compared with 100mg fostamatinib’s reduction of 720mg/g (n=16) and placebo’s reduction of 177mg/g (n=14). These trends were also observed among patients who entered the study with a baseline proteinuria of 2,000mg/g. During the study safety events were in-line with previous experiences, with two patients experiencing severe adverse events across each cohort and two events reported as drug related (pancreatitis and abnormal liver enzyme). As a reminder, fostamatinib has over 5,000 patient-years of experience generated with the drug. Going forward, Rigel plans to advance the IgAN program through collaborations with a pharmaceutical partner, which we believe could be potentially bundled with an ex-U.S. territory licensing of TAVLISSE for lead indication ITP." (4/3/2018)
2. According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (3/10/2018)

Who are some of Rigel Pharmaceuticals' key competitors?

Some companies that are related to Rigel Pharmaceuticals include Revance Therapeutics (RVNC), Dynavax Technologies (DVAX), Epizyme (EPZM), TG Therapeutics (TGTX), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), CytomX Therapeutics (CTMX), Athenex (ATNX), Zai Lab (ZLAB), Uniqure (QURE), MacroGenics (MGNX), Access Pharmaceuticals (ABEO), Biohaven Pharmaceutical (BHVN), Assembly Biosciences (ASMB), Alder BioPharmaceuticals (ALDR), Flexion Therapeutics (FLXN), Inflarx (IFRX) and Amphastar Pharmaceuticals (AMPH).

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the folowing people:

Mr. Raul R. Rodriguez, CEO, Pres & Director (Age 57)
Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 53)
Dr. Anne-Marie S. Duliege M.D., M.S., Chief Medical Officer and Exec. VP (Age 59)
Mr. Eldon C. Mayer III, Chief Commercial Officer and Exec. VP (Age 57)
Dr. Thomas A. Raffin, Co-Founder (Age 71)

Has Rigel Pharmaceuticals been receiving favorable news coverage?

News stories about RIGL stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Rigel Pharmaceuticals earned a coverage optimism score of 0.22 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 47.86 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $3.84.

How big of a company is Rigel Pharmaceuticals?

Rigel Pharmaceuticals has a market capitalization of $565.90 million and generates $4.48 million in revenue each year. The biotechnology company earns $-77,990,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Rigel Pharmaceuticals employs 103 workers across the globe.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]

MarketBeat Community Rating for Rigel Pharmaceuticals (RIGL)

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		248 (Vote Outperform)
Underperform Votes:		164 (Vote Underperform)
Total Votes:		412

MarketBeat's community ratings are surveys of what our community members think about Rigel Pharmaceuticals and other stocks. Vote "Outperform" if you believe RIGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RIGL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Rigel Pharmaceuticals (NASDAQ:RIGL) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

5 Wall Street analysts have issued ratings and price targets for Rigel Pharmaceuticals in the last 12 months. Their average twelve-month price target is $7.20, suggesting that the stock has a possible upside of 87.50%. The high price target for RIGL is $8.00 and the low price target for RIGL is $6.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$7.20	$6.00	$5.80	$6.75
Price Target Upside:	87.50% upside	42.52% upside	41.81% upside	108.98% upside

Rigel Pharmaceuticals (NASDAQ:RIGL) Consensus Price Target History

Price Target History for Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals (NASDAQ:RIGL) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/18/2018	BMO Capital Markets	Boost Price Target	Outperform -> Outperform	$6.00 -> $8.00	High
4/18/2018	Jefferies Group	Boost Price Target	Buy	$7.00	High
4/18/2018	HC Wainwright	Set Price Target	Buy	$8.00	High
4/17/2018	Cantor Fitzgerald	Set Price Target	Buy	$6.00	High
4/17/2018	Piper Jaffray	Boost Price Target	Overweight	$6.00 -> $7.00	High
8/3/2016	JPMorgan Chase	Reiterated Rating	Buy	$5.00	N/A
4/23/2016	Credit Suisse Group	Upgrade	Buy		N/A

(Data available from 4/22/2016 forward)

Rigel Pharmaceuticals (NASDAQ:RIGL) Earnings History and Estimates Chart

Earnings by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals (NASDAQ:RIGL) Earnings Estimates

2018 EPS Consensus Estimate: ($0.69)
2019 EPS Consensus Estimate: ($0.46)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.18)	($0.18)	($0.18)
Q2 2018	1	($0.18)	($0.18)	($0.18)
Q3 2018	2	($0.18)	($0.15)	($0.17)
Q4 2018	2	($0.18)	($0.14)	($0.16)
Q1 2019	1	($0.13)	($0.13)	($0.13)
Q2 2019	1	($0.12)	($0.12)	($0.12)
Q3 2019	1	($0.11)	($0.11)	($0.11)
Q4 2019	1	($0.10)	($0.10)	($0.10)

Rigel Pharmaceuticals (NASDAQ RIGL) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/30/2018		($0.16)					N/A
3/6/2018	Q4 2017	($0.13)	($0.18)	$0.05 million		View	Listen
11/7/2017	Q3 2017	($0.15)	($0.14)		$0.90 million	View	N/A
8/1/2017	Q2 2017	($0.15)	($0.16)	$2.05 million		View	Listen
5/2/2017	Q1 2017	($0.12)	($0.13)	$4.30 million	$3.58 million	View	Listen
3/7/2017	Q4 2016	($0.17)	($0.16)	$4.25 million	$3.00 million	View	Listen
11/1/2016	Q316	($0.23)	($0.24)	$3.97 million	$3.76 million	View	Listen
8/2/2016	Q216	($0.20)	($0.15)	$3.75 million	$8.60 million	View	N/A
5/3/2016	Q116	($0.19)	($0.19)	$4.00 million	$5.03 million	View	Listen
3/8/2016	Q415	($0.14)	($0.14)	$8.90 million	$8.50 million	View	Listen
11/3/2015	Q315	($0.17)	($0.08)	$5.00 million	$12.90 million	View	Listen
8/4/2015	Q215	($0.22)	($0.16)	$2.67 million	$5.18 million	View	Listen
5/7/2015	Q414	($0.18)	($0.21)	$16.00 million	$2.18 million	View	Listen
3/3/2015	Q4	($0.27)	($0.25)	$2.50 million	$8.25 million	View	N/A
11/4/2014	Q314	($0.27)	($0.24)	$1.70 million		View	N/A
8/5/2014	Q214	($0.25)	($0.29)	$1.05 million		View	N/A
5/7/2014	Q114	($0.25)	($0.25)	$0.43 million		View	N/A
3/4/2014	Q4 13	($0.25)	($0.19)		$5.80 million	View	N/A
11/5/2013	Q313	($0.29)	($0.27)	$260.00 million		View	N/A
8/6/2013	Q2 2013	($0.30)	($0.26)	$0.53 million	$1.40 million	View	N/A
5/7/2013	Q1 2013	($0.30)	($0.29)	$1.73 million		View	N/A
3/5/2013	Q4 2012	($0.32)	($0.30)			View	N/A
11/6/2012	Q312	($0.38)	($0.36)	$0.84 million		View	N/A
8/7/2012		($0.34)	($0.35)			View	N/A
5/1/2012		($0.33)	($0.32)			View	N/A
3/6/2012		($0.28)	($0.36)			View	N/A
11/1/2011		($0.28)	($0.25)			View	N/A
8/2/2011		($0.36)	($0.37)			View	N/A
5/3/2011		($0.36)	($0.40)			View	N/A
3/1/2011	Q4 2010	($0.36)	($0.33)			View	N/A
11/2/2010	Q3 2010	$0.58	$0.96			View	N/A
8/3/2010	Q2 2010	$0.45	$0.52			View	N/A
5/4/2010	Q1 2010	($0.06)	($0.43)			View	N/A
3/2/2010	Q4 2009	($0.45)	($0.48)			View	N/A
11/3/2009	Q3 2009	($0.56)	($0.70)			View	N/A
8/4/2009	Q2 2009	($0.80)	($0.81)			View	N/A
5/5/2009	Q1 2009	($0.97)	($0.80)			View	N/A
2/24/2009	Q4 2008	($0.96)	($0.91)			View	N/A
11/3/2008	Q3 2008	($0.75)	($1.03)			View	N/A
8/5/2008	Q2 2008	($0.66)	($0.93)			View	N/A
5/6/2008	Q1 2008	($0.58)	($0.79)			View	N/A
2/12/2008	Q4 2007	($0.44)	($0.61)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Rigel Pharmaceuticals (NASDAQ:RIGL) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Rigel Pharmaceuticals (NASDAQ RIGL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.38%
Institutional Ownership Percentage: 92.33%

Insider Trading History for Rigel Pharmaceuticals (NASDAQ:RIGL)

Institutional Ownership by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals (NASDAQ RIGL) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/3/2017	Ryan D Maynard	CFO	Sell	100,000	$3.90	$390,000.00	100,000
7/5/2017	Anne-Marie Duliege	Insider	Sell	5,000	$2.69	$13,450.00
8/30/2016	Donald G Payan	EVP	Sell	5,303	$4.00	$21,212.00
4/1/2015	Donald G Payan	EVP	Sell	10,000	$3.75	$37,500.00
12/18/2014	Dolly Vance	EVP	Sell	1,000	$2.22	$2,220.00
9/3/2014	Donald G Payan	EVP	Sell	20,000	$2.56	$51,200.00
11/19/2013	Bvf Partners P/Il	major shareholder	Sell	484,622	$2.64	$1,279,402.08
6/7/2013	Bvf Partners L P/Il	Major Shareholder	Buy	32,700	$3.47	$113,469.00
9/13/2012	Dolly Vance	EVP	Sell	4,151	$10.43	$43,294.93

(Data available from 1/1/2013 forward)

Rigel Pharmaceuticals (NASDAQ RIGL) News Headlines

Source:

Date	Headline
	Rigel Pharmaceuticals (RIGL) FDA Approval Of TAVALISSE(TM) - Slideshow seekingalpha.com - April 20 at 4:32 PM
	Rigel prices stock offering at $3.90; shares up 1% premarket seekingalpha.com - April 20 at 9:36 AM
	Jefferies Group Research Analysts Raise Earnings Estimates for Rigel Pharmaceuticals, Inc. (RIGL) www.americanbankingnews.com - April 20 at 8:52 AM
	Rigel Pharma (RIGL) Reports FDA Approval of TAVALISSE (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia www.streetinsider.com - April 19 at 9:26 AM
	2 Bay Area drug approvals in 1 day underscore industry's issues, opportunities www.bizjournals.com - April 18 at 4:46 PM
	Rigel Pharmaceuticals (RIGL) PT Raised to $8 at BMO Capital on FDA Approval www.streetinsider.com - April 18 at 4:46 PM
	Analysts See 100% Upside To Rigel After Tavalisse Approval finance.yahoo.com - April 18 at 4:45 PM
	2 Bay Area drug approvals in 1 day underscore industry's issues, opportunities finance.yahoo.com - April 18 at 4:45 PM
	Rigel Announces Proposed Public Offering Of Common Stock finance.yahoo.com - April 18 at 4:45 PM
	BMO Capital Markets Boosts Rigel Pharmaceuticals (RIGL) Price Target to $8.00 www.americanbankingnews.com - April 18 at 11:17 AM
	Jefferies Group Boosts Rigel Pharmaceuticals (RIGL) Price Target to $7.00 www.americanbankingnews.com - April 18 at 9:46 AM
	Rigel : FDA Okays TAVALISSE For Chronic Immune Thrombocytopenia In Adult www.nasdaq.com - April 18 at 9:26 AM
	Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients www.bizjournals.com - April 18 at 9:26 AM
	Rigel Overcomes Its First FDA Approval Barrier, Is There More To Come? seekingalpha.com - April 18 at 9:26 AM
	Rigel Pharmaceuticals (RIGL) Price Target Raised to $8.00 www.americanbankingnews.com - April 18 at 9:00 AM
	Rigel Pharmaceuticals (RIGL) PT Set at $6.00 by Cantor Fitzgerald www.americanbankingnews.com - April 18 at 8:37 AM
	Piper Jaffray Increases Rigel Pharmaceuticals (RIGL) Price Target to $7.00 www.americanbankingnews.com - April 17 at 9:20 PM
	Trading in Rigel halted ahead of expected FDA OK for Tavalisse for immune thrombocytopenia; shares up 10% seekingalpha.com - April 17 at 4:55 PM
	Here's Why Rigel Pharmaceuticals Rose as Much as 10.2% Today finance.yahoo.com - April 17 at 4:55 PM
	FDA approves Rigel Pharmaceuticals' drug for rare bleeding disorder finance.yahoo.com - April 17 at 4:55 PM
	Here's Why Rigel Pharmaceuticals Rose as Much as 10.2% Today finance.yahoo.com - April 17 at 4:55 PM
	Here’s What Happened Last Week In Biotech finance.yahoo.com - April 17 at 9:47 AM
	The Week Ahead: Netflix Earnings, Big Bank Results, FDA Actions Abound finance.yahoo.com - April 16 at 4:27 PM
	Rigel Pharmaceuticals, Inc. (RIGL) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - April 15 at 11:29 AM
	Rigel Pharmaceuticals (RIGL) Downgraded by ValuEngine to Sell www.americanbankingnews.com - April 15 at 10:59 AM
	Rigel Pharma (RIGL) April option implied volatility elevated into FDA action date www.streetinsider.com - April 13 at 4:31 PM
	Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why www.zacks.com - April 13 at 4:31 PM
	When Biotech Gets Even Riskier finance.yahoo.com - April 13 at 4:31 PM
	Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why finance.yahoo.com - April 13 at 4:31 PM
	Here's What Caused Rigel Pharmaceuticals' Wild Ride Today www.msn.com - April 13 at 9:49 AM
	News that made Rigel stock pop was a mistake, Rigel says www.marketwatch.com - April 13 at 9:49 AM
	Wild ride for Rigel Pharmaceuticals seekingalpha.com - April 12 at 4:28 PM
	Rigel Makes Statement Regarding Website Error finance.yahoo.com - April 12 at 4:28 PM
	Rigel Pharmaceuticals (RIGL) Given Buy Rating at Jefferies Group www.americanbankingnews.com - April 9 at 1:19 PM
	Rigel Fumbles A Phase 2, Can Stage A Potential Comeback With FDA Approval seekingalpha.com - April 9 at 9:39 AM
	BMO Capital Markets Reiterates Buy Rating for Rigel Pharmaceuticals (RIGL) www.americanbankingnews.com - April 8 at 10:49 AM
	Rigel Pharmaceuticals (RIGL) Raised to Sell at ValuEngine www.americanbankingnews.com - April 8 at 10:46 AM
	Why Rigel Is Worth A Look Despite Failed Study In IgAN seekingalpha.com - April 6 at 4:42 PM
	Rigel Pharma (RIGL) Says Phase 2 Study of Fostamatinib in IgA Did Not Achieve Statistical Significance for its Primary Endpoint www.streetinsider.com - April 5 at 9:05 AM
	Rigel Pharmaceuticals To Test The FDA seekingalpha.com - April 5 at 9:05 AM
	Rigel Pharmaceuticals, Inc. Expected to Earn Q3 2018 Earnings of ($0.15) Per Share (RIGL) www.americanbankingnews.com - April 5 at 7:54 AM
	Rigel Pharmaceuticals (RIGL) Updates on Fostamatinib Phase 2 In IgAN Top Line Results - Slideshow seekingalpha.com - April 4 at 5:00 PM
	Rigel (RIGL) Sinks on Failure of Mid-Stage Study on Lead Drug finance.yahoo.com - April 4 at 5:00 PM
	Zacks: Brokerages Expect Rigel Pharmaceuticals, Inc. (RIGL) to Announce -$0.17 EPS www.americanbankingnews.com - April 3 at 7:12 PM
	Pre-Open Movers 04/03: (MGI) (TSLA) (X) Higher; (LFIN) (SWCH) (RIGL) Lower (more...) www.streetinsider.com - April 3 at 4:32 PM
	Here's Why Rigel Pharmaceuticals Inc. Stock Is Slipping Today www.msn.com - April 3 at 4:32 PM
	Here's Why Rigel Pharmaceuticals Inc. Stock Is Slipping Today finance.yahoo.com - April 3 at 4:32 PM
	HC Wainwright Reiterates $7.00 Price Target for Rigel Pharmaceuticals (RIGL) www.americanbankingnews.com - April 3 at 3:35 PM
	Rigel Announces Topline Data from Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy finance.yahoo.com - April 3 at 9:44 AM
	Rigel Pharmaceuticals (RIGL) Upgraded by BidaskClub to "Hold" www.americanbankingnews.com - March 30 at 5:40 PM

Rigel Pharmaceuticals (NASDAQ:RIGL) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Rigel Pharmaceuticals (NASDAQ:RIGL) Income Statement, Balance Sheet and Cash Flow Statement

Rigel Pharmaceuticals (NASDAQ RIGL) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff